The name change from Ultimovacs ASA to Zelluna ASA has also been registered with the Norwegian Register of Business Enterprises. The name change and the first day of trading is expected to be implemented on Euronext Oslo Børs on or about 4 March 2025.

Related article

Ultimovacs combines its business with Zelluna Immunotherapy

Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.

The management team comprise Namir Hassan, CEO, Hans Vassgård Eid, CFO, Anders Holm, COO/Head of BD, Jens Bjørheim, CMO, Luise Weigand, Head of Research, Emilie Gauthy, Head of CMC, Øivind Foss, Head of Clinical Operations, and Julia Ino, Head of Project Management.

Listing on the Oslo Stock Exchange opens new doors for growth and innovation, enhances our visibility and provides the financial flexibility needed to accelerate the development of our groundbreaking cell therapies getting them closer to solid cancer patients who need them.

“Today marks a pivotal moment in Zelluna’s journey, as we are poised to enter the public markets. Through the unwavering dedication of our team, board and investors, we have pioneered the TCR-NK platform from basic research, to the public markets with an exciting, worlds first MAGE-A4 lead program heading towards the clinic. Listing on the Oslo Stock Exchange opens new doors for growth and innovation, enhances our visibility and provides the financial flexibility needed to accelerate the development of our groundbreaking cell therapies getting them closer to solid cancer patients who need them,” says Namir Hassan, the Chief Executive Officer of Zelluna ASA.

TCR-NK platform

Zelluna has built a platform to take the curative potential of cell therapies to solid cancers at a global scale. Zelluna does this through an “off the shelf” cell therapy platform, which merges clinically validated components – TCR targeting with NK cells – to form TCR-NK. This novel TCR-NK platform is protected by strong intellectual property opening up the potential for an unprecedented opportunity to capture the market of an entire therapeutic field. The lead asset nearing the clinic is a world’s first MAGE-A4 targeting TCR-NK which can potentially be used to treat a range of solid cancers with unmet medical need in high value cancer markets.